Import from "@/components/mdx"

Cytomel vs Compounded Liothyronine (T3): What Women Need to Know

Why This Comparison Matters for Women

Women are diagnosed with hypothyroidism at roughly five to eight times the rate of men, so the question of which T3 formulation to use is predominantly a women's health question. Your thyroid hormones interact with estrogen, progesterone, and the hypothalamic-pituitary-ovarian axis at every life stage. Getting the formulation wrong means getting the dose wrong, and in thyroid medicine, precision matters.

Most women start on levothyroxine (T4) and convert it to the active hormone triiodothyronine (T3) in peripheral tissues. A subset, particularly those with the DIO2 Thr92Ala polymorphism affecting deiodinase enzyme activity, may convert T4 to T3 inefficiently and remain symptomatic despite a normal TSH. That is the clinical rationale for adding liothyronine.

The Core Difference in Three Sentences

Branded Cytomel is an FDA-approved immediate-release tablet manufactured under strict Good Manufacturing Practice (GMP) standards. Compounded liothyronine is mixed by a licensed compounding pharmacy and is not subject to the same pre-market efficacy or bioequivalence testing. The clinical question is whether that regulatory difference translates into a meaningful difference in outcomes for you.

Branded Cytomel: What the Label Tells You

Cytomel (King Pharmaceuticals, now Pfizer) contains liothyronine sodium in 5 mcg, 25 mcg, and 50 mcg tablets. Each batch is tested for potency and dissolution. You know with a high degree of confidence that a 25 mcg tablet contains close to 25 mcg of active hormone.

Pharmacokinetics in Women

T3 is absorbed primarily from the jejunum. Oral bioavailability averages about 95% in fasted, euthyroid individuals. Peak serum T3 occurs within 2 to 4 hours of ingestion, and the half-life is roughly 24 hours. Because of that short half-life, twice-daily dosing blunts the post-dose T3 spike that can cause palpitations, and twice-daily dosing is the standard clinical practice for most women.

Sex-specific pharmacokinetics matter here. Women have a higher volume of distribution for T3 than men in proportion to body weight, and estrogen increases thyroxine-binding globulin (TBG), which sequesters both T3 and T4. Women on combined oral contraceptives may need higher total thyroid hormone replacement doses because estrogen raises TBG, leaving less free hormone available.

Dosing Guidance for Women

The FDA-approved starting dose is 25 mcg per day, but most endocrinologists and thyroid-experienced clinicians initiate at 5 mcg once or twice daily, particularly in perimenopausal women and those with cardiovascular risk, titrating by 5 mcg every one to two weeks. The American Thyroid Association's 2014 guidelines note that the typical full replacement dose of T3 when used as monotherapy is 25 to 75 mcg per day, though combination T4/T3 therapy usually uses much lower T3 fractions.

Compounded Liothyronine: The Case For and Against

Compounded formulations exist because branded Cytomel is immediate-release only. A single dose produces a peak serum T3 that can be two to three times the normal physiological range within hours, which is the reason some women experience heart pounding, anxiety, or heat intolerance even at low doses.

Slow-Release Compounded T3

Compounding pharmacies offer slow-release (SR) liothyronine in capsule form, using excipients such as hydroxypropyl methylcellulose to delay absorption over 6 to 12 hours. The appeal is a flatter pharmacokinetic curve. A small crossover study by Idrees et al. (2020) found that SR liothyronine produced lower peak T3 concentrations compared with immediate-release T3, though it also produced lower overall T3 exposure in some participants.

The problem: absorption varies significantly between pharmacies. Two women taking 20 mcg from two different compounding pharmacies may absorb 14 mcg and 22 mcg respectively. No FDA-mandated bioequivalence standard applies. A 2013 JAMA Internal Medicine analysis of compounded thyroid products found substantial variability in hormone content, with some products deviating more than 15% from the stated dose.

When Compounded T3 Is Clinically Justified

Compounding is reasonable in specific, narrow circumstances:

• Allergy to a branded Cytomel excipient (acacia, sodium starch glycolate)
• Need for a dose that is not commercially available (for example, 2.5 mcg in a child or a highly sensitive adult)
• Clinical need for a slow-release formulation to reduce cardiovascular side effects in a woman with documented palpitations on immediate-release T3
• Shortage of branded product

Outside these scenarios, the Endocrine Society's 2016 clinical practice guideline on thyroid dysfunction does not recommend compounded thyroid products as a first-line choice, citing quality-control concerns.

The Evidence on T3 Therapy: What Trials Actually Show

The key trial in T3 combination therapy is Bunevicius et al. (NEJM 1999). In a crossover study of 33 patients with hypothyroidism, replacing 50 mcg of levothyroxine with 12.5 mcg of liothyronine produced improvements in mood, cognition, physical symptoms, and neuropsychological performance compared with T4 alone. The authors stated: "Substitution of liothyronine for a portion of levothyroxine in patients with hypothyroidism may improve their quality of life."

That finding generated enormous clinical enthusiasm. The subsequent decade of replication attempts produced a more complicated picture.

Trials That Did Not Replicate the Bunevicius Finding

• Sawka et al. (2003, Journal of Clinical Endocrinology and Metabolism): No significant improvement in quality of life with T4/T3 combination in 46 patients over 15 weeks.
• Appelhof et al. (2005, JCEM): Combination therapy produced modest weight loss and preference by patients, but no improvement on standard quality-of-life scales at usual doses.
• Idrees et al. (2020, NEJM Evidence): SR liothyronine did not significantly improve quality of life versus T4 alone at 12 months in the RESTORE trial.

What This Means for You

The honest summary: some women do feel better on T4/T3 combination and the Bunevicius data suggest a real physiological signal. But large, well-powered trials have not confirmed a consistent benefit across unselected hypothyroid populations. The women most likely to benefit may be those with genetic impairment in T4-to-T3 conversion, thyroid-cancer survivors whose thyroid has been fully removed, or women with persistent symptoms despite optimized T4. This is an area where the data in women specifically is limited by small trial sizes, and most published trials enrolled fewer than 100 participants.

Sex-Specific Physiology: How Your Hormones Change T3 Needs

Reproductive Years

During the follicular phase of your menstrual cycle, rising estrogen increases TBG, modestly lowering free T3 and free T4. Most women compensate without noticing. Women with subclinical or overt hypothyroidism may notice more fatigue and heavier periods in the luteal phase when thyroid reserve is low. PCOS is associated with higher rates of autoimmune thyroid disease, affecting roughly 25% of women with PCOS compared with about 7% of age-matched controls. If you have PCOS and are on liothyronine, your insulin resistance may also affect T3 metabolism via altered deiodinase activity.

Trying to Conceive

Optimal thyroid function is essential for ovulation and implantation. The American Thyroid Association's 2017 guidelines on thyroid disease in pregnancy recommend a TSH below 2.5 mIU/L in women who are actively trying to conceive. T3 is not recommended as the primary replacement during preconception because it does not cross the placenta effectively and the fetus depends on maternal T4 for early brain development.

Perimenopause

This is the life stage where T3 therapy carries the most risk if not carefully managed. Perimenopausal women already have an increased baseline risk for atrial fibrillation and bone loss. T3 excess accelerates both. A large Danish cohort study found that suppressed TSH from overtreatment was associated with a 2.3-fold increased risk of atrial fibrillation in older patients. Bone mineral density may decline more rapidly with even mildly supratherapeutic T3 in postmenopausal women who are not on hormone therapy. If you are perimenopausal and prescribed T3, your clinician should check TSH every 6 to 8 weeks during titration and perform baseline DEXA and cardiovascular risk assessment before starting.

Postmenopause

The reference range for TSH shifts with age. Many guidelines now accept a TSH of up to 4 to 6 mIU/L as appropriate in women over 70 without symptoms, meaning older postmenopausal women are more likely to be overtreated if T3 is added without rechecking targets. The Menopause Society (formerly NAMS) does not have a specific T3 position statement, but its cardiovascular health guidance underscores that even subclinical thyrotoxicosis increases cardiovascular risk in postmenopausal women.

Pregnancy and Lactation Safety (Required Reading)

If you are pregnant or planning pregnancy, read this section before your next prescription refill.

Pregnancy

Liothyronine is pregnancy category A for thyroid replacement when used in physiologic doses, but branded or compounded T3 as a standalone replacement is not the appropriate formulation in pregnancy. Here is why: the placenta contains high concentrations of type 3 deiodinase, which converts T3 to the inactive reverse T3, protecting the fetus from maternal T3 surges. The fetus relies on maternal T4 as the precursor for its own T3 production. Women on liothyronine monotherapy who become pregnant should transition to levothyroxine under specialist supervision before conception if possible, or as soon as pregnancy is confirmed.

The ATA 2017 pregnancy guidelines explicitly state that T4 is the treatment of choice for hypothyroidism during pregnancy and that women on T3-containing regimens should be transitioned before or early in pregnancy. Uncontrolled hypothyroidism in the first trimester is associated with a 2.5-fold increase in miscarriage risk and with fetal neurodevelopmental impairment.

If you are on combination T4/T3 therapy and become unexpectedly pregnant, call your clinician the same day. Do not stop your thyroid medication. Switch the T3 component to an equivalent T4 dose as directed by your provider.

Lactation

T3 does transfer into breast milk. Milk concentrations of T3 are measurable but low, and in euthyroid infants the exposure from a mother on replacement doses is unlikely to be clinically significant. Nonetheless, infants of mothers on liothyronine should have thyroid function checked at the routine newborn screen and again at 2 to 4 weeks if the mother is on doses above 25 mcg per day. The Academy of Breastfeeding Medicine considers levothyroxine compatible with breastfeeding; the data on liothyronine specifically is limited.

Contraception

Liothyronine does not require mandatory contraception in the way a known teratogen like methimazole does. The concern is different: T3 at supratherapeutic levels increases basal metabolic rate, can disrupt the hypothalamic-pituitary-ovarian axis, and may reduce the efficacy signal of hormonal contraceptives by altering sex hormone-binding globulin. Women on hormonal contraception may need higher liothyronine doses because estrogen raises TBG. If you switch contraceptive methods, recheck your thyroid panel within 6 to 8 weeks.

Who This Is Right For and Who Should Avoid It

Women Most Likely to Benefit from Adding T3

• You have autoimmune hypothyroidism (Hashimoto's), have been on optimized levothyroxine for at least 6 months, your TSH and free T4 are in range, and you still have significant fatigue, cognitive fog, or depression that your clinician and you have evaluated for other causes
• You had a total thyroidectomy for thyroid cancer and cannot convert T4 to T3 via the thyroid gland itself
• You carry the DIO2 Thr92Ala variant (testable via clinical genetics) and have documented low-normal free T3 on adequate T4 replacement
• You have tried multiple levothyroxine brands and still feel symptomatic

Women Who Should Not Use Liothyronine

• You are pregnant or actively trying to conceive (use levothyroxine instead)
• You have uncontrolled atrial fibrillation or recent acute coronary syndrome
• Your TSH is already low-normal or suppressed on current therapy
• You are postmenopausal with osteoporosis or osteopenia and are not on bone-protective therapy
• You have a history of anxiety disorder or panic disorder that worsens with adrenergic stimulation

Compounded vs Branded: A Direct Comparison

| Feature | Branded Cytomel | Compounded Liothyronine | |---|---|---| | FDA approval | Yes | No | | Bioequivalence testing | Required | Not required | | Dose options | 5, 25, 50 mcg | Virtually any dose | | Release profile | Immediate only | Immediate or slow-release | | Potency consistency | High | Variable | | Insurance coverage | Often covered | Rarely covered | | Evidence base | Moderate (multiple RCTs) | Limited | | Cost without insurance | $30 to $80/month | $40 to $120/month (pharmacy-dependent) |

Monitoring: What Your Labs Should Show

Whether you are on branded or compounded T3, your monitoring schedule should include:

• TSH and free T3 at 6 to 8 weeks after any dose change. Free T3 matters here in a way it does not for T4-only therapy. You want free T3 in the upper half of the reference range, not above it.
• Free T4 to confirm you are not overreplacing the T4 component if on combination therapy.
• Resting heart rate and blood pressure at each visit. A resting heart rate above 90 in a previously rate-controlled woman is a signal to reduce dose.
• Annual DEXA in perimenopausal and postmenopausal women on any liothyronine-containing regimen, particularly if TSH is at the lower end of normal.
• Lipid panel annually; thyroid hormone strongly influences LDL clearance, and inadequate replacement raises LDL while overreplacement raises HDL.

The Endocrine Society's 2016 guideline on hypothyroidism recommends checking TSH 6 to 8 weeks after initiating or adjusting liothyronine because of its shorter half-life relative to levothyroxine.

The Evidence Gap: What We Do Not Know Yet

Women have been under-represented in thyroid combination therapy trials. The Bunevicius trial enrolled 33 patients, sex breakdown not prominently reported. The RESTORE trial enrolled 75 patients. A 2019 systematic review in Thyroid found that no published RCT of combination T4/T3 therapy was powered to detect sex-specific differences in outcomes.

We do not have good data on whether perimenopausal women respond differently to T3 combination therapy than premenopausal women. We do not know the optimal free T3 target in women with Hashimoto's disease at different life stages. The compounded slow-release literature consists of a handful of studies, none larger than 100 participants, and none with women-specific subgroup analyses.

This is not a reason to avoid T3 therapy if you have a clear clinical indication. It is a reason to insist on individualized monitoring and to treat any response as provisional until your labs and symptoms confirm it is working.

Practical Steps Before Your Next Appointment

Ask your clinician these specific questions:

1. Is my free T3 in the upper half of the reference range on my current regimen?
2. Have we checked for the DIO2 Thr92Ala variant given my persistent symptoms?
3. If I am perimenopausal, has my bone density been checked in the last two years?
4. If I am prescribed compounded slow-release T3, which accredited pharmacy is it coming from, and is it PCAB-accredited?

The Pharmacy Compounding Accreditation Board (PCAB) accreditation is the closest quality signal available for compounded products. It does not guarantee bioequivalence, but it does confirm adherence to USP Chapter 795 and 797 standards.

Your TSH alone is insufficient monitoring if you are on any T3-containing regimen. Insist on free T3 measurement at each dose-change check.